Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists

Table 3

Treatment.

TREATMENT
Haemorrhage treatment N (%)
(i) None	16 (30.8%)
(ii) Vitamin K	6 (11.5%)
(iii) Prothrombin	0 (0%)
(iv) Prothrombin and vitamin K	26 (50%)
(v) Surgical	4 (7.7%)
Treatment at discharge N (%)
(i) None	10 (41.6%)
(ii) Antiplatelet agents	3 (12.5%)
(iii) VKAs	2 (8.3%)
(iv) VKAs and antiplatelet agents	0 (0%)
(v) Dabigatran	2 (8.3%)
(vi) Rivaroxaban	0 (0%)
(vii) Apixaban	0 (0%)
(viii) NOAC and aspirin	0 (0%)
(ix) LAA closure	5 (20.8)
(x) Prophylactic heparin
Treatment at 3 months N (%)
(i) None	0 (0%)
(ii) Antiplatelet agents	2 (9.1%)
(iii) VKAs	2 (9.1%)
(iv) VKAs and antiplatelet agents	0 (0%)
(v) Dabigatran	4 (18.2%)
(vi) Rivaroxaban	7 (31.8 %)
(vii) Apixaban	2 (9.1%)
(viii) NOAC and aspirin	0 (0%)
(ix) LAA closure	3 (13.6%)
(x) Prophylactic heparin	1 (4.5%)
Treatment changed 3 months after discharge.	15/22

VKA: Vitamin K antagonist. NOAC: novel oral anticoagulant. LAA: left atrial appendage.